CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.
- SPP raised A$606,150 at A$0.018 per share
- 33.7 million new shares to be issued
- Funds target China market launch and R&D
- SPP shares priced 10% below placement
- Placement proceeds total A$5 million
Share Purchase Plan Closes with Moderate Take-Up
CurveBeam AI Limited (ASX:CVB) has concluded its Share Purchase Plan (SPP), raising A$606,150 from eligible shareholders. The SPP offered shares at 1.8 cents each, a 10% discount to the recent A$5 million placement price, resulting in the issuance of 33.7 million new shares on 4 September 2026. While the amount raised is modest compared to the placement, it reflects steady shareholder support ahead of the company’s strategic initiatives.
Capital to Accelerate China Launch and Product Enhancements
The combined funds from the SPP and the prior placement will be channelled into several key areas: marketing and sales efforts, particularly preparing for the HiRise™ CT scanner’s entry into the Chinese market; research and development to enhance the product; and supply chain readiness for the China launch. This aligns with CurveBeam AI’s ongoing push to expand its footprint in one of the world’s largest healthcare markets.
Strategic Positioning Amid Previous Capital Raises
This SPP follows a recent A$5 million placement, which itself was part of a broader capital raising strategy to support CurveBeam AI’s growth trajectory. The company has previously secured significant investments, including a strategic partnership with WEGO Orthopaedics, underscoring its commitment to penetrating the Chinese market. The modest uptake in the SPP contrasts with the larger placement but provides additional liquidity and shareholder participation in the company’s next phase.
Share Issuance and Potential Shortfall Placement
CurveBeam AI reserves the right to place any shortfall shares at its discretion, subject to regulatory compliance. This flexibility allows the company to optimise capital structure and investor base as it advances its commercial objectives. The exact allocation of any shortfall shares remains to be announced, adding an element of uncertainty to the final capital mix.
Bottom Line?
CurveBeam AI’s latest capital raise modestly boosts resources for its China launch and product upgrades, but the relatively low SPP uptake hints at cautious shareholder appetite ahead.
Questions in the middle?
- Will CurveBeam AI accelerate its China launch timeline with the new funds?
- How will the company allocate any shortfall shares from the SPP?
- What impact will the capital raise have on CurveBeam AI’s cash runway and R&D progress?